IL319946A - Use of a bispecific anti-CLDN4/anti-CD137 antibody in combination with a PD-1 signaling inhibitor for cancer treatment - Google Patents
Use of a bispecific anti-CLDN4/anti-CD137 antibody in combination with a PD-1 signaling inhibitor for cancer treatmentInfo
- Publication number
- IL319946A IL319946A IL319946A IL31994625A IL319946A IL 319946 A IL319946 A IL 319946A IL 319946 A IL319946 A IL 319946A IL 31994625 A IL31994625 A IL 31994625A IL 319946 A IL319946 A IL 319946A
- Authority
- IL
- Israel
- Prior art keywords
- cldn4
- bispecific antibody
- cancer treatment
- antibody combined
- signal inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022167362 | 2022-10-19 | ||
| PCT/JP2023/037616 WO2024085166A1 (ja) | 2022-10-19 | 2023-10-18 | がん治療におけるpd-1シグナル阻害剤との組み合わせによる抗cldn4-抗cd137二重特異性抗体の使用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL319946A true IL319946A (en) | 2025-05-01 |
Family
ID=90737914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL319946A IL319946A (en) | 2022-10-19 | 2023-10-18 | Use of a bispecific anti-CLDN4/anti-CD137 antibody in combination with a PD-1 signaling inhibitor for cancer treatment |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4606384A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7730432B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20250089513A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119997975A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023365438A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2025001156A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL319946A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2025004457A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202426503A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2024085166A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026042803A1 (ja) * | 2024-08-21 | 2026-02-26 | アステラス製薬株式会社 | がん治療におけるプラチナ系薬剤との組み合わせによる抗cldn4-抗cd137二重特異性抗体の使用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ES2539411T3 (es) | 1999-08-23 | 2015-06-30 | Dana-Farber Cancer Institute, Inc. | PD-1, receptor para la B7-4 y su utilización |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| WO2008114733A1 (ja) | 2007-03-16 | 2008-09-25 | Kyowa Hakko Kirin Co., Ltd. | 抗Claudin-4抗体 |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| PL2346994T3 (pl) | 2008-09-30 | 2022-04-19 | Ablexis, Llc | Myszy knock-in do wytwarzania chimerycznych przeciwciał |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| EP2707723B1 (en) | 2011-05-12 | 2016-02-10 | Genentech, Inc. | Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| BR112015007184A2 (pt) | 2012-10-02 | 2017-08-08 | Bristol Myers Squibb Co | combinação de anticorpos anti-kir e anticorpos anti-pd-1 para tratar câncer |
| MX380176B (es) * | 2014-04-07 | 2025-03-12 | Chugai Pharmaceutical Co Ltd | Molecula ligada a antigeno inmunoactivada. |
| EP3064507A1 (en) * | 2015-03-06 | 2016-09-07 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof |
| RU2727165C2 (ru) | 2015-05-04 | 2020-07-21 | ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ | Слитый полипептид с противораковой активностью |
| BR112018071612A2 (pt) * | 2016-04-22 | 2019-02-19 | Alligator Bioscience Ab | polipeptídeos biespecíficos inovadores contra cd137 |
| PH12022552323A1 (en) * | 2020-03-31 | 2023-12-04 | Chugai Pharmaceutical Co Ltd | Claudin-6 targeting multispecific antigen-binding molecules and uses thereof |
| CN116133684B (zh) | 2020-05-27 | 2025-07-18 | 阿里亚利斯治疗公司 | 抗人nr1抗体衍生物 |
| IL307744A (en) * | 2021-04-22 | 2023-12-01 | Astellas Pharma Inc | Anti-CLDN4/anti-CD137 bispecific antibody |
-
2023
- 2023-10-18 CN CN202380073096.1A patent/CN119997975A/zh active Pending
- 2023-10-18 EP EP23879809.4A patent/EP4606384A1/en active Pending
- 2023-10-18 IL IL319946A patent/IL319946A/en unknown
- 2023-10-18 KR KR1020257015107A patent/KR20250089513A/ko active Pending
- 2023-10-18 WO PCT/JP2023/037616 patent/WO2024085166A1/ja not_active Ceased
- 2023-10-18 TW TW112139704A patent/TW202426503A/zh unknown
- 2023-10-18 AU AU2023365438A patent/AU2023365438A1/en active Pending
- 2023-10-18 JP JP2024551825A patent/JP7730432B2/ja active Active
-
2025
- 2025-04-15 MX MX2025004457A patent/MX2025004457A/es unknown
- 2025-04-16 CL CL2025001156A patent/CL2025001156A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2025004457A (es) | 2025-05-02 |
| AU2023365438A1 (en) | 2025-04-17 |
| JPWO2024085166A1 (cg-RX-API-DMAC7.html) | 2024-04-25 |
| TW202426503A (zh) | 2024-07-01 |
| WO2024085166A1 (ja) | 2024-04-25 |
| CN119997975A (zh) | 2025-05-13 |
| JP7730432B2 (ja) | 2025-08-27 |
| CL2025001156A1 (es) | 2025-05-23 |
| EP4606384A1 (en) | 2025-08-27 |
| KR20250089513A (ko) | 2025-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL316867A (en) | Macrocyclic KRAS inhibitors for cancer treatment | |
| EP3906061A4 (en) | METHODS OF TREATMENT OF CANCER USING COMBINATIONS OF PARP INHIBITORS AND ANTIBODY RADIOCONJUGATE | |
| IL327418A (en) | RAS-PI3K inhibitors for the treatment of cancer and immunological diseases | |
| EP4242207A4 (en) | Kras inhibitors for treatment of cancers | |
| IL285050A (en) | Administering PD-1 inhibitors for the treatment of skin cancer | |
| IL316829A (en) | Menin-MLL inhibitors for cancer treatment | |
| IL307744A (en) | Anti-CLDN4/anti-CD137 bispecific antibody | |
| CA3270683A1 (en) | Use of anti-cldn4/anti-cd137 bispecific antibody combined with pd-1 signal inhibitor for cancer treatment | |
| HUE067601T2 (hu) | PD-1 inhibitorok intraléziós beadása a bõrrák kezelésére | |
| PH12022550585A1 (en) | Methods of treating cancer by the use of pd-1 axis inhibitors and anti-periostin antibodies | |
| IL313864A (en) | Methods for treating recurrent ovarian cancer using bispecific antibodies against MUC16 and against CD3 alone or in combination with antibodies against PD-1 | |
| AU2024362771A1 (en) | Combination treatment of prostate cancers with two bispecific antibodies | |
| CA3266666A1 (en) | SHP-1 INHIBITORS FOR CANCER TREATMENT | |
| CA3304766A1 (en) | Methods of treating cancer by administering anti-pd-l1/anti-4-1bb bispecific antibodies | |
| HK40088568A (en) | Methods of treating cervical cancer by administering the pd-1 inhibitor antibody cemiplimab | |
| EP4031129A4 (en) | COMBINATION OF A SMALL MOLECULE INHIBITOR OF PD-1/PD-L1 INTERACTION AND ANTI-PD-1 ANTIBODIES FOR THE TREATMENT OF CANCER | |
| CA3306323A1 (en) | Anti-pd-l1 and anti-4-1bb bispecific antibody for treating tumors | |
| CA3289052A1 (en) | Use of an anti-tgf.beta.r2/pd-1 bispecific antibody to treat cancer | |
| TW202617776A (zh) | 治療smarcb1缺陷型癌症之方法 | |
| IL327531A (en) | Use of anti-SIRP-alpha antibodies for cancer treatment | |
| CA3307105A1 (en) | Use of anti-sirp-alpha antibodies to treat cancer | |
| HK40090320A (en) | Treatment of cancer using a cea cd3 bispecific antibody and a tgfbeta signaling inhibitor | |
| HK40091622A (en) | Bispecific antibodies for use in treatment of nlrc4-gof inflammasomapathy | |
| IL320200A (en) | Antibodies for cancer treatment anti-BSSL | |
| HK40096277A (en) | Methods of treating cancer by administering a pd-1 inhibitor |